Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Author:
Allanore Yannick1, Khanna Dinesh2ORCID, Smith Vanessa3ORCID, Aringer Martin4ORCID, Hoffmann-Vold Anna-Maria5ORCID, Kuwana Masataka6ORCID, Merkel Peter A7, Stock Christian8, Sambevski Steven9, Denton Christopher P10ORCID, Bergna M, Casado G, Mannucci Walter P, Proudman S, Stevens W, Thakkar V, Troy L, Loeffler-Ragg J, Olschewski H, André B, Bondue B, Houssiau F, Smith V, Wuyts W, Azevedo V, Johnson S, Keystone E, Khalidi N, Levesque M, Rozas R Maturana, Silva Orellana A, Huang C, Li J, Jiang Z, Liu Y, Xiao W, Xu J, Zeng X, Zheng Y, Zou H, Becvar R, Madsen H, Søndergaard K, Kilpeläinen M, Myllärniemi M, Agard C, Allanore Y, Bourdin A, Cottin V, Crestani B, Diot E, Dominique S, Hachulla E, Jouneau S, Leroy S, Nunes H, Prevot G, Wallaert B, Wemeau L, Aringer M, Bewig B, Blaas S, Distler J, Ehrchen J, Ewert R, Gläser S, Henes J, Hunzelmann N, König R, Kötter I, Kreuter M, Prasse A, Schulze-Koops H, Sfikakis P, Vlachoyiannopoulos P, Losonczy G, Behera D, Gayathri Devi H J, Kadel J, Kawedia M, Kumar D, Kumar U, Lokhande R, Malpani A, Mohan M, Nalawade A, Parakh U, Swarnakar R, Shobha V, Thangakunam B, Udwadia Z, Henry M, O'Reilly K, Balbir-Gurman A, Kramer M, Litinsky I, Rosner I, Cutolo M, Gabrielli A, Iaccarino L, Pesci A, Riccieri V, Vettori S, Funakubo Y, Inoue Y, Kawakami A, Kawaguchi Y, Kawamura T, Kondoh Y, Kuwana M, Nanki T, Nishioka Y, Nozawa K, Ogura T, Okamoto M, Sano H, Sasai R, Sasaki N, Suda T, Takahashi H, Takeuchi T, Makino S, Tanaka S, Yamasaki Y, Ch'ng S S, Cheah C, Kan S, Raja Mohamed R B, Selman M, de Vries-Bouwstra J K, van den Toorn L, Vonk M, Voskuyl A E, Hoffmann-Vold A M, Seip M, Dankiewicz-Fares I, Olesiejuk R, Pulka G, Szepietowski J, Alves J, Bernardes M, Cordeiro A, Costa J, Neves S, Salvador M J, Alegre Sancho J, Carreira Delgado P, Castellví Barranco I, Cifrián Martínez J, Guillén del Castillo A, Ovalles J G, López-Longo F J, Rivera Gallego A, Freire Dapena M C, Román Ivorra J A, Ekwall A-K H, Maurer B, Mihai C M, Müller R, Mahakkanukrauh A, Nantiruj K, Siripaitoon B, Denton C P, Herrick A, Madhok R, Maher T M, West A, Antin-Ozerkis D, Bascom R, Criner G, Csuka M E, Dematte D'Amico J, Ettinger N, Fischer A, Gerbino A, Gerke A, Glassberg M, Glazer C, Golden J, Gripaldo R, Gupta N, Hamblin M, Highland K, Ho L, Huggins J T, Hummers L, Jones L, Kahaleh M, Khanna D, Kim H, Lancaster L H, Luckhardt T, Mayes M, Mendoza Ballesteros F, Mooney J, Mohabir P, Morrissey B, Moua T, Padilla M, Patel N, Perez R, Roman J, Rossman M, Russell T, Saketkoo L, Shah A, Shlobin O, Scholand M B, Simms R, Spiera R, Steen V, Veeraraghavan S, Weigt S,
Affiliation:
1. Department of Rheumatology, Paris Cité University, APHP, Cochin Hospital , Paris, France 2. Department of Medicine, University of Michigan , Ann Arbor, MI, USA 3. Department of Rheumatology and Internal Medicine, Ghent University Hospital and Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC) , Ghent, Belgium 4. Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, Dresden , Dresden, TU, Germany 5. Department of Rheumatology, Oslo University Hospital , Oslo, Norway 6. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine , Tokyo, Japan 7. Division of Rheumatology, Department of Medicine, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania , Philadelphia, PA, USA 8. Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach, Germany 9. Boehringer Ingelheim International GmbH , Ingelheim am Rhein, Germany 10. Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London , London, UK
Abstract
Abstract
Objectives
To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc).
Methods
In the SENSCIS trial, patients with SSc-ILD were randomized to receive nintedanib or placebo. Patients who completed the SENSCIS trial were eligible to enter SENSCIS-ON, in which all patients received open-label nintedanib.
Results
Among 277 patients with lcSSc treated in the SENSCIS trial, the rate (s.e.) of decline in forced vital capacity (FVC; ml/year) over 52 weeks was −74.5 (19.2) in the placebo group and −49.1 (19.8) in the nintedanib group (difference: 25.3 [95% CI −28.9, 79.6]). Among 249 patients with data at week 52, mean (s.e.) change in FVC at week 52 was −86.4 (21.1) ml in the placebo group and −39.1 (22.2) ml in the nintedanib group. Among 183 patients with lcSSc who participated in SENSCIS-ON and had data at week 52, mean (s.e.) change in FVC from baseline to week 52 of SENSCIS-ON was −41.5 (24.0) ml in patients who took placebo in the SENSCIS trial and initiated nintedanib in SENSCIS-ON and −45.1 (19.1) ml in patients who took nintedanib in the SENSCIS trial and continued it in SENSCIS-ON.
Conclusion
Patients with lcSSc may develop progressive fibrosing ILD. By targeting pulmonary fibrosis, nintedanib slows decline in lung function in patients with lcSSc and ILD.
Trial registration
ClinicalTrials.gov (https://clinicaltrials.gov), NCT02597933 and NCT03313180
Funder
Boehringer Ingelheim International GmbH
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|